Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus

JAMA

Volumn 301, Issue 15, 2009, Pages 1565-1572

  Whitmer, Rachel A ^a   Karter, Andrew J ^a   Yaffe, Kristine ^b   Quesenberry, Charles P ^a   Selby, Joseph V ^a  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DEMENTIA; DISEASE ASSOCIATION; EMERGENCY WARD; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; AGED; COMORBIDITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; COMORBIDITY; DEMENTIA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; LONGITUDINAL STUDIES; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 64749114159     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.460     Document Type: Article

References (60)

1. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64-74.
2. Launer LJ. Diabetes and brain aging: epidemiologic evidence. Curr Diab Rep. 2005;5(1):59-63.
3. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460-2469.
4. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol. 2004;490(1-3):169-175.
5. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep. 2007;7(5):373-380.
6. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab Res Rev. 2004;20(suppl 2): S32-S42.
7. Draelos MT, Jacobson AM, Weinger K, et al. Cognitive function in patients with insulin-dependent diabetes mellitus during hyperglycemia and hypoglycemia. Am J Med. 1995;98(2):135-144.
8. Warren RE, Frier BM. Hypoglycaemia and cognitive function. Diabetes Obes Metab. 2005;7(5): 493-503.
9. Kaufman FR, Epport K, Engilman R, Halvorson M. Neurocognitive functioning in children diagnosed with diabetes before age 10 years. J Diabetes Complications. 1999;13(1):31-38.
10. Wredling R, Levander S, Adamson U, Lins PE. Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man. Diabetologia. 1990;33(3):152-157.
11. Jacobson AM, Musen G, Ryan CM, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007; 356(18):1842-1852.
12. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline [published online ahead of print December 16, 2008]. J Clin Endocrinol Metab. doi:10.1210/jc .2008-1410.
13. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57(12):3169-3176.
14. Cryer PE. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [author reply 194-196]. Diabetes Care. 2007;30(1):190-192.
15. Ryan CM, Williams TM, Finegold DN, Orchard TJ. Cognitive dysfunction in adults with type 1 (insulindependent) diabetes of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia. 1993;36(4):329-334.
16. Suh SW, Hamby AM, Swanson RA. Hypoglycemia, brain energetics, and hypoglycemic neuronal death. Glia. 2007;55(12):1280-1286.
17. Karter AJ, Newman B, Rowell SE, et al. Large scale collection of family history data and recruitment of informative families for genetic analysis. J Regist Manage. 1998;25(1):7-12.
18. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287 (19):2519-2527.
19. Karter AJ, Stevens MR, Gregg EW, et al. Educational disparities in rates of smoking among diabetic adults: the translating research into action for diabetes study. Am J Public Health. 2008;98(2):365-370.
20. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of selfmonitoring of blood glucose. Diabetes Care. 2006; 29(8):1757-1763.
21. Karter AJ. Role of self-monitoring of blood glucose in glycemic control. Endocr Pract. 2006;12 (suppl 1):110-117.
22. Karter AJ, Ahmed AT, Liu J, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Delea et al [author reply 852-853]. Diabetes Care. 2004;27(3):850-851.
23. Selby JV, Karter AJ, Ackerson LM, Ferrara A, Liu J. Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. Diabetes Care. 2001; 24(9):1547-1555.
24. Ettner SL, Cadwell BL, Russell LB, et al. Investing time in health: do socioeconomically disadvantaged patients spend more or less extra time on diabetes selfcare [published online ahead of print August 15, 2008]? Health Econ. doi:10.1002/hec.1394.
25. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23(5): 588-594.
26. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82(5):703-710.
27. Gordon NP, Kaplan GA. Some evidence refuting the HMO "favorable selection" hypothesis: the case of Kaiser Permanente. Adv Health Econ Health Serv Res. 1991;12:19-39.
28. Hiatt RA, Friedman GD. Characteristics of patients referred for treatment of end-stage renal disease in a defined population. Am J Public Health. 1982; 72(8):829-833.
29. Karter AJ, Ackerson LM, Darbinian JA, et al. Selfmonitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes Registry. Am J Med. 2001;111(1):1-9.
30. Karter AJ, Birner CR, Ackerson LM, et al. The epidemiology of self-monitoring of blood glucose in insulin taking diabetics: the Northern California Kaiser Permanente Diabetes Registry. Diabetes. 1997.
31. Selby JV. Linking automated databases for research in managed care settings. Ann Intern Med. 1997; 127(8 pt 2):719-724.
32. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997;20 (9):1396-1402.
33. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4.
34. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-281.
35. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330(7504): 1360.
36. Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res. 2007;4(2):103-109.
37. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24(5):353-363.
38. Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007;117(4): 868-870.
39. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71(14):1057-1064.
40. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3(3):169-178.
41. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005;26(suppl 1):65-69.
42. Craft S, Asthana S, Schellenberg G, et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci. 2000;903:222-228.
43. Farris W, Mansourian S, Chang Y, et al. Insulindegrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100(7):4162-4167.
44. Kulstad JJ, McMillan PJ, Leverenz JB, et al. Effects of chronic glucocorticoid administration on insulindegrading enzyme and amyloid-beta peptide in the aged macaque. J Neuropathol Exp Neurol. 2005; 64(2):139-146.
45. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis. 2006;10 (1):89-109.
46. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38: UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-713.
47. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol. 2004;490(1-3):169-175.
48. Cosway R, Strachan MW, Dougall A, Frier BM, Deary IJ. Cognitive function and information processing in type 2 diabetes. Diabet Med. 2001;18(10): 803-810.
49. Deary IJ, Frier BM. Severe hypoglycaemia and cognitive impairment in diabetes. BMJ. 1996;313(7060): 767-768.
50. Deary IJ, Crawford JR, Hepburn DA, Langan SJ, Blackmore LM, Frier BM. Severe hypoglycemia and intelligence in adult patients with insulin-treated diabetes. Diabetes. 1993;42(2):341-344.
51. McNay EC. The impact of recurrent hypoglycemia on cognitive function in aging. Neurobiol Aging. 2005;26(suppl 1):76-79.
52. Jarjour IT, Ryan CM, Becker DJ. Regional cerebral blood flow during hypoglycaemia in children with IDDM. Diabetologia. 1995;38(9):1090-1095.
53. Artola A, Kamal A, Ramakers GM, et al. Synaptic plasticity in the diabetic brain: advanced aging? Prog Brain Res. 2002;138:305-314.
54. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000; 23(11):542-549.
55. Klein JP, Waxman SG. The brain in diabetes: molecular changes in neurons and their implications for end-organ damage. Lancet Neurol. 2003;2(9): 548-554.
56. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008; 7(2):184-190.
57. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351-357.
58. Chalmers J, Kengne AP, Joshi R, Perkovic V, Patel A. New insights from ADVANCE. J Hypertens Suppl. 2007;25(1):S23-S30.
59. Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ. Prevalence of dementia in older Latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc. 2003;51 (2):169-177.
60. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol. 2003;38(9): 941-946. (doi:10.1001/jama.2009.470)